Gufic Biosciences Q2 FY26 Risks

Revenue ₹237 Cr

EBITDA ₹38 Cr

PAT ₹17 Cr

EBITDA Margin 16%

Duration 56 min

Read Time 1 min read

✓ Verified against BSE filing

Risk Intelligence

Material risks this quarter

Concise cards keep the risk register scannable while preserving evidence-level context in the underlying quarter data.

Risks

Slower CMO transition to Indore

CMO clients are slow to shift to Indore due to audit and validation requirements; only 4 of 12-14 major clients onboarded so far.

medium · management_commentary

Revenue growth stagnation due to product mix shifts

Q2 revenue was flat QoQ despite higher volumes, as lower-priced products (e.g., pantoprazole, vancomycin) replaced higher-priced ones (e.g., teicoplanin).

medium · data_observation

Pricing erosion in domestic critical care

API price pass-through is eroding top-line growth in critical care and SPAR, with value growth of only 5-6% despite higher unit growth.

low · management_commentary

USFDA/ EU GMP audit delays for Indore

EU GMP and UK MHRA audits targeted for Q1 FY27, but USFDA timeline remains uncertain; any delay could impact international revenue ramp-up.

medium · analyst_question

Gufic Biosciences Limited — Q2 FY26